AI Article Synopsis

  • This study aimed to find the best average liver biologically effective dose (BED) that can help prevent radiation-induced liver disease (RILD) during stereotactic body radiation therapy (SBRT).
  • It analyzed treatment plans for 50 patients with liver tumors and used a model to convert physical doses to BED, exploring how these doses relate to the liver's tolerability and the planning target volume (PTV).
  • The results showed that specific mean BED values (73 Gy for Child-Pugh A patients and 16 Gy for B patients) effectively prevent RILD, with strong correlations found between the mean doses and PTVs.

Article Abstract

Aim: The purpose of this study was to determine the optimal mean liver biologically effective dose (BED) to prevent radiation-induced liver disease (RILD) in stereotactic body radiation therapy (SBRT).

Background: The actual mean doses appropriate for liver irradiation in modern radiotherapy techniques have not been adequately investigated, although SBRT is sometimes alternatively performed using fractionated regimens.

Materials And Methods: SBRT treatment plans for liver tumors in 50 patients were analyzed. All distributions of the physical doses were transformed to BED using the linear-quadratic model. The relationship between physical doses and the BED for the liver were then analyzed, as was the relationship between the mean BED for the liver and the planning target volume (PTV).

Results: A significantly positive correlation was observed between the mean physical dose for the background liver and the mean BED for the whole liver ( < 0.0001,  = 0.9558). Using the LQ model, a mean BED of 73 and 16 Gy for the whole liver corresponded to the hepatic tolerable mean physical dose of 21 and 6 Gy for Child-Pugh A- and B-classified patients, respectively. Additionally, the PTV values were positively correlated with the BEDs for the whole liver ( < 0.0001,  = 0.8600), and the background liver ( < 0.0001,  = 0.7854).

Conclusion: A mean BED of 73 and 16 Gy for the whole liver appeared appropriate to prevent RILD in patients with Child-Pugh classes A and B, respectively. The mean BED for the liver correlated well with the PTV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422009PMC
http://dx.doi.org/10.1016/j.rpor.2017.02.011DOI Listing

Publication Analysis

Top Keywords

bed liver
12
liver
9
effective dose
8
radiation-induced liver
8
physical doses
8
bed
5
validation liver
4
dose
4
liver dose
4
dose terms
4

Similar Publications

This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose.

View Article and Find Full Text PDF

Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-based combinations. The present systematic review and study-level meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).

View Article and Find Full Text PDF

Circulating tumor DNA (ctDNA) can be used to assess treatment response in patients with undifferentiated pleomorphic sarcoma (UPS). The importance of this is explored in our case of a 75-year-old man who was diagnosed with UPS of the right kidney. After a right nephrectomy and tumor resection, the patient was recovering well with initially undetectable, and then slightly elevated, circulating tumor DNA.

View Article and Find Full Text PDF

Background: Laparoscopic cholecystectomy (LC) is currently the gold standard of care for managing gallstone disease. The time taken to perform LC depends on both patient-related and surgeon-related factors. Recognizing factors associated with difficult LC (DLC) can aid in appropriate surgeon selection and judicious scheduling of cases.

View Article and Find Full Text PDF

AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review.

Gastroenterology

December 2024

Division of Gastroenterology and Hepatology, Department of Medicine, Endeavor Health, Chicago, Illinois.

Description: Portal vein thromboses (PVTs) are common in patients with cirrhosis and are associated with advanced portal hypertension and mortality. The treatment of PVTs remains a clinical challenge due to limited evidence and competing risks of PVT-associated complications vs bleeding risk of anticoagulation. Significant heterogeneity in PVT phenotype based on anatomic, host, and disease characteristics, and an emerging spectrum of therapeutic options further complicate PVT management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!